Abstract
The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repurposing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, antihistaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A inhibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting.
Keywords: COVID-19; Corticosteroid; Drug repurposing; Heparin; Inflammatory bowel disease; Septic shock.
【저자키워드】 Corticosteroid, COVID-19, Drug repurposing, heparin, Inflammatory bowel disease, Septic shock, 【초록키워드】 Corticosteroid, Drug repurposing, antibodies, Corticosteroids, vaccination, clinical trial, Drug discovery, SARS-CoV-2 pandemic, clinical trials, Blood cells, drug, heparin, Inflammatory bowel disease, Shock, clinical, Septic shock, Central nervous system, transcriptomic data, public health emergency, inhibitor, COVID-19 patients, compounds, Anticoagulants, COVID-19 patient, corticosteroids), SCN5A, healthy subjects, priority, treat, clinical setting, whole blood cells, de novo, bowel, approach, septic, analyzed, identify, examined, addition, faster, conditions, mandatory, patients with COVID-19, whole blood cell, 【제목키워드】 Analysis,